International Neoadjuvant Melanoma Consortium

John Fruehauf, M.D., PhD,discusses the International Neoadjuvant Melanoma Consortuim. Author: Annual-Meeting Added: 08/21/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts

Related Links:

No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research
Public Workshop
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
Purpose of review The aim of this review is to provide an overview of the current development of immuno-oncology in the (neo)adjuvant setting. Recent findings Several checkpoint inhibitors (CPis) have been approved for the treatment of advanced solid cancers, mostly for unresectable metastatic setting. Thus, the next logical step is to explore the potential of CPi in earlier stages of the disease. Summary There are currently many ongoing trials investigating immunotherapy agents in the early setting in various tumor types, involving various CPis and other innovative immunotherapies, as well as combinations with eit...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research
The new recommendations will help standardize  neoadjuvant clinical trial methodology and develop a path for regulatory review and approval of neoadjuvant therapies in melanoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
CONCLUSION: Neoadjuvant BRAF-targeted therapy is associated with a high pCR rate in patients with stage III-IV melanoma, which may correlate with improved RFS and OS. This article is protected by copyright. All rights reserved. PMID: 31329344 [PubMed - as supplied by publisher]
Source: Pigment Cell and Melanoma Research - Category: Cytology Authors: Tags: Pigment Cell Melanoma Res Source Type: research
Condition:   Cutaneous Melanoma Intervention:   Drug: Atezolizumab Sponsors:   Ashley Holder, MD;   Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cutaneous Melanoma Intervention:   Drug: Atezolizumab Sponsors:   Ashley Holder, MD;   Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cutaneous Melanoma Intervention:   Drug: Atezolizumab Sponsors:   Ashley Holder, MD;   Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cutaneous Melanoma Intervention:   Drug: Atezolizumab Sponsors:   Ashley Holder, MD;   Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cutaneous Melanoma Intervention:   Drug: Atezolizumab Sponsors:   Ashley Holder, MD;   Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Melanoma | Neoadjuvant Therapy | Skin Cancer